Evaluation of risk factors and biomarkers related to arterial and venous thrombotic events in idiopathic inflammatory myopathies

Notarnicola, A.; Barsotti, Simone; Näsman, L; Tang, Qingqin; Holmqvist, Marie; Lundberg, IE; Antovič, Aleksandra

doi:10.1080/03009742.2020.1861647

Cited by 5 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For each year of age, there was a 3.5% increased chance of experiencing a thrombotic event in patients with IIM. In their cohort of 253 patients with IIM, only 6% had anti-phospholipid antibodies, with no significant difference between the patients and comparators [ 47 ].…”

Section: Methodsmentioning

confidence: 99%

Cardiovascular manifestations in idiopathic inflammatory myopathies

et al. 2023

View full text Add to dashboard Cite

Cardiovascular involvement in idiopathic inflammatory myopathies (IIM) is an understudied area which is gaining increasing recognition in recent times. Recent advances in imaging modalities and biomarkers have allowed the detection of subclinical cardiovascular manifestations in IIM. However, despite the availability of these tools, the diagnostic challenges and underestimated prevalence of cardiovascular involvement in these patients remain significant. Notably, cardiovascular involvement remains one of the leading causes of mortality in patients with IIM. In this narrative literature review, we outline the prevalence and characteristics of cardiovascular involvement in IIM. Additionally, we explore investigational modalities for early detection of cardiovascular involvement, as well as newer approaches in screening to facilitate timely management. Key points• Cardiac involvement in IIM in majority cases is subclinical and a major cause of mortality.• Cardiac magnetic resonance imaging is sensitive for detection of subclinical cardiac involvement.

show abstract

Section: Methodsmentioning

confidence: 99%

Cardiovascular manifestations in idiopathic inflammatory myopathies

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The results of a prospective study conducted by FATHI et al showed that the prevalence of ILD was as high as 78% in patients with PM/DM [ 110 ], and although there is some discrepancy between this result and other similar studies [ 111 , 112 ], they all indicate that the lungs are the most frequently involved organ in PM/DM patients and that PM/DM patients with ILD have a poorer prognosis compared with PM/DM patients alone [ 113 ]. Several studies have demonstrated an increased risk of VTE in patients with PM/DM [ 114 – 116 ], especially within the first 5 years of disease diagnosis [ 114 , 117 ], the reason for which may be related to the active systemic inflammatory response and the fact that the disease has not been effectively controlled. In addition, DM is a microvascular disease mediated by the involvement of body fluids, so vascular endothelial damage during the course of the disease in DM patients may also play a role in the development of VTE [ 114 ], which may contribute to a higher risk of VTE in DM-ILD compared to PM-ILD, but there is a lack of large-scale clinical data to support this.…”

Section: Vte Associated With Ctd-ildmentioning

confidence: 99%

Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE

Jiang,

Jia,

Dong

2024

Thrombosis J

View full text Add to dashboard Cite

As an autoimmune disease, the persistent systemic inflammatory response associated with connective tissue disease (CTD) is involved in the development of venous thromboembolism (VTE). However, clinical data showed that the risk of VTE in patients differed between subtypes of CTD, suggesting that different subtypes may have independent mechanisms to promote the development of VTE, but the specific mechanism lacks sufficient research at present. The development of pulmonary fibrosis also contributes to the development of VTE, and therefore, patients with CTD-associated interstitial lung disease (CTD-ILD) may be at higher risk of VTE than patients with CTD alone or patients with ILD alone. In addition, the activation of the coagulation cascade response will drive further progression of the patient’s pre-existing pulmonary fibrosis, which will continue to increase the patient’s risk of VTE and adversely affect prognosis. Currently, the treatment for CTD-ILD is mainly immunosuppressive and antirheumatic therapy, such as the use of glucocorticoids and janus kinase-inhibitors (JAKis), but, paradoxically, these drugs are also involved in the formation of patients’ coagulation tendency, making the clinical treatment of CTD-ILD patients with a higher risk of developing VTE challenging. In this article, we review the potential risk factors and related mechanisms for the development of VTE in CTD-ILD patients to provide a reference for clinical treatment and prevention.

show abstract

“…52,54 The analysis of 281,264 AstraZeneca COVID-19 vaccinees in Denmark and Norway reported 59 cases of venous thromboembolism, which is 11 cases greater than the expected 30 cases per 100,000 persons. 55 7) The impaired innate and acquired immunity of severe liver disease patients results in decreased response to any vaccination. 57 Studies have reported increased vaccine efficacy when doubling the dose of hepatitis B vaccination in cirrhotic patients.…”

Section: Covid-19 Vaccination Strategies In Chronic Liver Disease Patientsmentioning

confidence: 99%

Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline

et al. 2021

View full text Add to dashboard Cite

Evaluation of risk factors and biomarkers related to arterial and venous thrombotic events in idiopathic inflammatory myopathies

Cited by 5 publications

References 31 publications

Cardiovascular manifestations in idiopathic inflammatory myopathies

Cardiovascular manifestations in idiopathic inflammatory myopathies

Under the dual effect of inflammation and pulmonary fibrosis, CTD-ILD patients possess a greater susceptibility to VTE

Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline

Contact Info

Product

Resources

About